July 19, 2016

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Key Points

Key points are not available for this paper at this time.

Abstract

Osimertinib may represent a clinically significant treatment option for patients with EGFRm NSCLC and brain metastases. Further investigation of osimertinib in this patient population is ongoing. Clin Cancer Res; 22(20); 5130-40. ©2016 AACR.

AI에게 질문

Bookmark

Cite This Study

Ballard et al. (Tue,) studied this question.

synapsesocial.com/papers/69d8a2748c03fbaff8befb9f https://doi.org/https://doi.org/10.1158/1078-0432.ccr-16-0399

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib2005 · 230 citations
2Site-specific metastasis of mouse melanomas and a fibrosarcoma in the brain or meninges of syngeneic animals.1988 · 118 citations
3Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man2004 · 130 citations
4Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation2010 · 110 citations
5Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT2009 · 207 citations

AI에게 질문

Bookmark